Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood-Brain Barrier-Towards a Mechanistic IVIVE-Based Approach

被引:32
作者
Ball, Kathryn [1 ]
Bouzom, Francois [1 ,4 ]
Scherrmann, Jean-Michel [2 ,3 ]
Walther, Bernard [1 ]
Decleves, Xavier [2 ,3 ]
机构
[1] Grp Rech Servier, Ctr Pharmacocinet & Metab, Orleans, France
[2] Univ Paris 05, Neuropsychopharmacol Addict CNRS UMR 8206, Fac Pharm, Paris, France
[3] INSERM, U705, Paris, France
[4] Technol Servier, F-45000 Orleans, France
来源
AAPS JOURNAL | 2013年 / 15卷 / 04期
关键词
blood-brain barrier; central nervous system; in vitro-in vivo extrapolation; PBPK; pharmacokinetics; CANCER RESISTANCE PROTEIN; CENTRAL-NERVOUS-SYSTEM; IN-VITRO MODELS; CEREBROSPINAL-FLUID CONCENTRATION; TARGETED ABSOLUTE PROTEOMICS; P-GLYCOPROTEIN TRANSPORT; INTERINDIVIDUAL VARIABILITY; ZIDOVUDINE TRANSPORT; DISTRIBUTED MODEL; EFFLUX TRANSPORT;
D O I
10.1208/s12248-013-9496-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Predicting the penetration of drugs across the human blood-brain barrier (BBB) is a significant challenge during their development. A variety of in vitro systems representing the BBB have been described, but the optimal use of these data in terms of extrapolation to human unbound brain concentration profiles remains to be fully exploited. Physiologically based pharmacokinetic (PBPK) modelling of drug disposition in the central nervous system (CNS) currently consists of fitting preclinical in vivo data to compartmental models in order to estimate the permeability and efflux of drugs across the BBB. The increasingly popular approach of using in vitro-in vivo extrapolation (IVIVE) to generate PBPK model input parameters could provide a more mechanistic basis for the interspecies translation of preclinical models of the CNS. However, a major hurdle exists in verifying these predictions with observed data, since human brain concentrations can't be directly measured. Therefore a combination of IVIVE-based and empirical modelling approaches based on preclinical data are currently required. In this review, we summarise the existing PBPK models of the CNS in the literature, and we evaluate the current opportunities and limitations of potential IVIVE strategies for PBPK modelling of BBB penetration.
引用
收藏
页码:913 / 932
页数:20
相关论文
共 135 条
  • [51] Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models
    Hatherell, Kathryn
    Couraud, Pierre-Olivier
    Romero, Ignacio A.
    Weksler, Babette
    Pilkington, Geoffrey J.
    [J]. JOURNAL OF NEUROSCIENCE METHODS, 2011, 199 (02) : 223 - 229
  • [52] Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models
    Hellinger, Eve
    Veszelka, Szilvia
    Toth, Andrea E.
    Walter, Fruzsina
    Kittel, Agnes
    Bakk, Monika Laura
    Tihanyi, Karoly
    Hada, Viktor
    Nakagawa, Shinsuke
    Thuy Dinh Ha Duy
    Niwa, Masami
    Deli, Maria A.
    Vastag, Monika
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 82 (02) : 340 - 351
  • [53] Quantitative Atlas of Blood-Brain Barrier Transporters, Receptors, and Tight Junction Proteins in Rats and Common Marmoset
    Hoshi, Yutaro
    Uchida, Yasuo
    Tachikawa, Masanori
    Inoue, Takashi
    Ohtsuki, Sumio
    Terasaki, Tetsuya
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) : 3343 - 3355
  • [54] Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data
    Hsiao, P
    Sasongko, L
    Link, JM
    Mankoff, DA
    Muzi, M
    Collier, AC
    Unadkat, JD
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) : 704 - 710
  • [55] In vitro-to-in vivo prediction of p-glycoprotein-based drug interactions at the human and rodent blood- brain barrier
    Hsiao, Peng
    Bui, Tot
    Ho, Rodney J. Y.
    Unadkat, Jashvant D.
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (03) : 481 - 484
  • [56] Quantitative Membrane Protein Expression at the Blood-Brain Barrier of Adult and Younger Cynomolgus Monkeys
    Ito, Katsuaki
    Uchida, Yasuo
    Ohtsuki, Sumio
    Aizawa, Sanshiro
    Kawakami, Hirotaka
    Katsukura, Yuki
    Kamiie, Junichi
    Terasaki, Tetsuya
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) : 3939 - 3950
  • [57] A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
    Jamei, Masoud
    Dickinson, Gemma L.
    Rostami-Hodjegan, Amin
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (01) : 53 - 75
  • [58] Challenges for blood-brain barrier (BBB) screening
    Jeffrey, P.
    Summerfield, S. G.
    [J]. XENOBIOTICA, 2007, 37 (10-11) : 1135 - 1151
  • [59] Assessment of the blood-brain barrier in CNS drug discovery
    Jeffrey, Phil
    Summerfield, Scott
    [J]. NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 33 - 37
  • [60] Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position
    Kalvass, J. C.
    Polli, J. W.
    Bourdet, D. L.
    Feng, B.
    Huang, S-M
    Liu, X.
    Smith, Q. R.
    Zhang, L. K.
    Zamek-Gliszczynski, M. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 80 - 94